Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer-Reference-Cited by-同舟云学术

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Published:2021-11 Issue:2 Volume:163 Page:246-253
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Shah Payal D.,Wethington Stephanie L.,Pagan Cheyenne,Latif Nawar,Tanyi Janos,Martin Lainie P.,Morgan Mark,Burger Robert A.,Haggerty Ashley,Zarrin Haley,Rodriguez Diego,Domchek Susan,Drapkin Ronny,Shih Ie-Ming,Smith Simon A.,Dean Emma,Gaillard Stéphanie,Armstrong Deborah,Torigian Drew A.,Hwang Wei-Ting,Giuntoli Robert,Simpkins Fiona

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference52 articles.

1. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study;Rose;Gynecol. Oncol.,2003

2. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study;Rose;J. Clin. Oncol.,1998

3. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer;Mutch;J. Clin. Oncol.,2007

4. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer;Ferrandina;J. Clin. Oncol.,2008

5. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study;Gynecologic Oncology;Gynecol. Oncol.,2006

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches;Translational Oncology;2024-12

2. Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells;Cancer Chemotherapy and Pharmacology;2024-09-14

3. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20

4. Identification of epigenetic modifiers essential for growth and survival of AML1/ETO‐positive leukemia;International Journal of Cancer;2024-08-15

5. Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer;Scientific Reports;2024-07-29